Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

EnGeneIC closes oversubscribed Series B financing

EnGeneIC closes oversubscribed Series B financing

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

UT Southwestern researchers find new potential target for halting tumor growth

UT Southwestern researchers find new potential target for halting tumor growth

Two orphan receptor proteins exert fatal double whammy effect against glioblastoma cells

Two orphan receptor proteins exert fatal double whammy effect against glioblastoma cells

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

New MIT study implicates RNA-binding proteins in regulation of cancer

New MIT study implicates RNA-binding proteins in regulation of cancer

New statistical model enables better identification of different cell types in solid tumors

New statistical model enables better identification of different cell types in solid tumors

Brunel scientists find way to target hard-to-reach cancers using 'Trojan horse' nanoparticles

Brunel scientists find way to target hard-to-reach cancers using 'Trojan horse' nanoparticles

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.